Markers for nutrition studies: Review of criteria for the evaluation of markers

European Journal of Nutrition

Volumn 52, Issue 7, 2013, Pages 1685-1699

  De Vries, Jan ^a   Antoine, Jean Michel ^b   Burzykowski, Tomasz ^c,d   Chiodini, Alessandro ^d   Gibney, Mike ^e   Kuhnle, Gunter ^f,g   Méheust, Agnès ^d,h   Pijls, Loek ⁱ   Rowland, Ian ^g  

^a De Vries Nutrition Solutions ^*  (Netherlands)

^b DANONE RESEARCH   (France)

^c HASSELT UNIVERSITY   (Belgium)

^d INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^e International Life Sciences Institute of Europe   (Belgium)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

^g UNIVERSITY OF READING   (United Kingdom)

^h Department of Movement Sciences   (France)

ⁱ NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Criteria; Evaluation; Marker; Nutrition research

Indexed keywords

BIOLOGICAL MARKER;

CHRONIC DISEASE; DIETARY INTAKE; DISEASE MARKER; FEEDING BEHAVIOR; HUMAN; INTERVENTION STUDY; NUTRITIONAL ASSESSMENT; NUTRITIONAL SCIENCE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; NUTRITIONAL STATUS; REPRODUCIBILITY OF RESULTS;

EID: 84885482910     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-013-0553-3     Document Type: Review

References (68)

1. Aggett PJ, Antoine JM, Asp NG, Bellisle F, Contor L, Cummings JH, Howlett J, Müller DJG, Persin C, Pijls LTJ et al (2005) Passclaim, consensus on criteria. Eur J Nutr 44:1-30
2. Potischman N, Freudenheim JL (2003) Biomarkers of nutritional exposure and nutritional status: an overview. J Nutr 133:S3873-S3874
3. Potischman N (2003) Biologic and methodologic issues for nutritional biomarkers. J Nutr 133:3875S-3880S
4. Marshall JR (2003) Methodologic and statistical considerations regarding use of biomarkers of nutritional exposure in epidemiology. J Nutr 133:S3881-S3887
5. Biomarkers definitions working group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95
6. Wagner JA (2008) Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 48:631-651
7. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A (2010) Biomarkers and surrogate end points-The challenge of statistical validation. Nat Rev Clin Oncol 7:309-317
8. Temple RJ (1995)Aregulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT (eds) Clinical measurement in drug evaluation. John Wiley and Sons, New York, pp 3-22
9. National research council (2010) Evaluation of biomarkers and surrogate endpoints in chronic disease. The National Academies Press, Washington
10. D'Agostino RB, Campbell MJ, Greenhouse JB (2006) Surrogate markers: back to the future. Stat Med 25:181-182
11. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431-440
12. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK (1990) Biomarkers as intermediate end points in chemoprevention trials. J Nat Cancer Inst 82:555-560
13. Boissel JP, Collet JP, Moleur P, Haugh M (1992) Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 43:235-244
14. Rolan P (1997) The contribution of clinical pharmacology surrogates and models to drug development-A critical appraisal. Br J Clin Pharmacol 44:219-225
15. Temple R (1999) Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282:790-795
16. Lesko LJ, Atkinson AJ (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347-366
17. Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182-188
18. Sistare FD, Dieterle F, Troth S et al (2010) Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 28:446-454
19. Freedman LS, Schatzkin A (1992) Sample size for studying intermediate endpoints within intervention trials or observational studies. Am J Epidemiol 136:1148
20. Buyse M, Molenberghs G (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029
21. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H (2000) The validation of surrogate endpoints in meta-Analyses of randomized experiments. Biostatistics 1:49-67
22. Burzykowski T, Buyse M (2006) Surrogate threshold effect: an alternative measure for meta-Analytic surrogate endpoint validation. Pharmaceutical Statisti 5:173-186
23. Ransohoff DF (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 60:1205-1219
24. Lassere MN, Johnson KR, Boers M et al (2007) Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 34:607-615
25. Bouxsein ML, Delmas PD, Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Mineral Res 23:1155-1167
26. Altar CA, Amakye D, Bounos D et al (2008) A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin Pharmacol Ther 83:368-371
27. Liang MH, Simard JF, Costenbader K et al (2009) Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus. Endocr Metab Immune Disord Drug Targets 9:108-112
28. Hlatky MA, Greenland P, Arnett DK et al (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408-2416
29. National Cancer Institute. Division of Cancer Prevention (2008) The Early Detection Research Network. http://edrn.nci.nih.gov/docs/progress-reports/edrn- 4th-report-200801.pdf/. Accessed 6 September 2011
30. Doust J, Doust J (2010) Qualification versus validation of biomarkers. Scand J Clin Lab Invest 242:40-43
31. Validity of surrogate endpoints in oncology (2011) Validity of surrogate endpoints in oncology. http://www.iqwig.de. Accessed 21 September 2011
32. Blanck HM, Bowman BA, Cooper GR et al (2003) Laboratory issues: use of nutritional biomarkers. J Nutr 133:888S-894S
33. Mayne ST (2003) Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr 133:S3933-S3940
34. Mason JB (2003) Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr 133:S3941-S3947
35. Lampe JW (2003) Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133:S3956-S3964
36. Livingstone MBE, Black AE (2003) Markers of the validity of reported energy intake. J Nutr 133:895S-920S
37. Bingham SA (2003) Urine nitrogen as a biomarker for the validation of dietary protein intake. J Nutr 133:921S-924S
38. Arab L (2003) Biomarkers of fat and fatty acid intake. J Nutr 133:925S-932S
39. Hambidge M (2003) Biomarkers of trace mineral intake and status. J Nutr 133:948S-955S
40. Foreword Willett W (2009) The validity of dietary assessment methods for use in epidemiologic studies. Br J Nutr 102:S1-S2
41. Henr?́quez-Sánchez P, Sánchez-Villegas A, Doreste-Alonso J et al (2009) Dietary assessment methods for micronutrient intake: a systematic review on vitamins. Br J Nutr 102:S10-S37
42. Serra-Majem L, Pfrimer K, Doreste-Alonso J et al (2009) Dietary assessment methods for intakes of iron, calcium, selenium, zinc and iodine. Br J Nutr 102:S38-S55
43. Overby NC, Serra-Majem L, Andersen LF (2009) Dietary assessment methods on n-3 fatty acid intake: a systematic review. Br J Nutr 102:S56-S63
44. Ortiz-Andrellucchi A, Doreste-Alonso J, Henr?́quez-Sánchez P, Cetin I, Serra-Majem L (2009) Dietary assessment methods for micronutrient intake in pregnant women: a systematic review. Br J Nutr 102:S64-S86
45. Ortiz-Andrellucchi A, Henr?́quez-Sánchez P, Sánchez-Villegas A et al (2009) Dietary assessment methods for micronutrient intake in infants, children and adolescents: a systematic review. Br J Nutr 102:S87-S117
46. Ortiz-Andrellucchi A, Sánchez-Villegas A, Doreste-Alonso J et al (2009) Dietary assessment methods for micronutrient intake in elderly people: a systematic review. Br J Nutr 102:S118-S149
47. Hooper L, Ashton K, Harvey LJ et al (2009) Assessing potential biomarkers of micronutrient status by using a systematic review methodology: methods. Am J Clin Nutr 89(suppl):S1953-S1959
48. Hill AB (1965) The Environment and Disease: association or Causation? Proc R Soc Med 58:295-300
49. Biesalski HK, J Aggett P, Anton R, et al (2010) Scientific substantiation of health claims: Evidence-based nutrition. 26th Hohenheim Consensus Conference, September 11, 2010 Nutrition 27:S1-S20
50. Burzykowski T, Molenberghs G, Buyse M et al (2001) Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J Roy Stat Soc 50:405-422
51. Collette L, Burzykowski T, Carroll KJ et al (2005) Is prostatespecific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and Astra- Zeneca Pharmaceuticals. J Clin Oncol 23:6139-6148
52. Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670
53. Buyse M, Burzykowski T, Carroll K et al (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224
54. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992
55. Buyse ME, Squifflet P, Allard SE et al. (2008) Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Hematologica 93(suppl 1):209
56. Lassere MN (2008) The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 17:303-340
57. Lee JW, Devanarayan V, Barrett YC et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23:312-328
58. Blumberg J, Heaney RP, Huncharek M et al (2010) Evidencebased criteria in the nutritional context. Nutr Rev 68:478-484
59. Raiten DJ, Namasté S, Brabin B et al (2011) Executive summary- biomarkers of nutrition for development: building a consensus. Am J Clin Nutr 94:633S-650S
60. Gallagher AM, Meijer GW, Richardson DP et al (2011) A standardised approach towards PROving the efficacy of foods and food constituents for health CLAIMs (PROCLAIM): providing guidance. Br J Nutr 106:S16-S28
61. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605-613
62. Fleming TR (2005) Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24:67-78
63. Abu-Asab MS, Chaouchi M, Alesci S et al (2011) Biomarkers in the age of omics: time for a systems biology approach. OMICS 15:105-112
64. O'Sullivan A, Gibney MJ, Brennan L (2011) Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies. Am J Clin Nutr 93:314-321
65. van Ommen B, Keijer J, Heil SG, Kaput J (2009) Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res 53:795-804
66. Rasnake CM, Trumbo PR, Heinonen TM (2008) Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. Nutr Rev 66:76-81
67. Goodsaid F, Frueh F (2007) Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 9:E105-E108
68. Molenberghs G, Burzykowski T, Alonso A, Buyse M (2004) A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 13(3):177-206